Lophius Biosciences Launches Interactive T Cell Tools Product Finder and Online Order Portal
Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell-based research tools and diagnostic systems for functional assessment of pathogen/disease-reactive T cells, has launched of its new T Cell Tools product line together with its new e-commerce online order portal. The new web-based customer interface at www.Lophius.com has been designed to provide an intuitive product selection and online order platform accelerating the ability of customers to quickly identify and select products from Lophius’ continuously growing portfolio.
T Cell Tools comprise selected research reagents to allow easy and reliable T cell stimulation, as well as robust quantification and monitoring of cell mediated immune responses (CMI). Different antigens from various pathogens with a current focus on the human cytomegalovirus (HCMV) and Epstein-Barr Virus (EBV) are well coordinated and validated to jointly contribute to a standardized and reliable read-out system. Hence, the individual product modules of T Cell Tools offer modular and complementary solutions for optimal assay performance.
Today, T Cell Tools include, amongst, peptide pools, lysates an proteins, a panel of T-activated antigens - complete proteins that are formulated using Lophius’ proprietary T-activation technology platform facilitating uptake and processing of the proteins via the canonical MHC class-I cross-presentation pathway. As a result, clinically relevant effector cells of the CMI such as CD4- and CD8-positve T cells as well as NK, and NKT cells will be activated. Optionally, customers may also combine their antigens with a matching IFN-gamma ELISPOT T-Track basic kit to reach maximum sensitivity and specificity upon measuring pathogen specific T cells.
Lophius aims to quickly expand the panel of antigens, antibodies, conjugates and read-out options to offer its customers a very comprehensive panel of relevant and well coordinated tools in near future to booster T cell research. Customers include researchers and clinicians in the field of immunology, infectious diseases, transplantation, clinical virology, oncology, autoimmune diseases, gynecology, and intensive care who need optimal performance by using either the standardized in-vitro diagnostic kit T-Track CMV or an individually compiled T cell activity assay based on the robust T-Track technology.
“We are very excited to announce the launch of our e-commerce portal as we believe it will provide our customers greater access to Lophius’ products at their convenience,” said Dr Robert Phelps, CEO of Lophius Biosciences. “With our intuitive product finder, consumers can browse and order some of the most innovative T cell products on the market” added Prof. Ralf Wagner, Chairman of the Board.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance